Formulations targeting the transmembrane protein CD19 and B-cell maturation antigen (BCMA) are now approved for hematologic diseases, but development is also underway for solid tumors, and HER2 is included as a candidate target antigen. The gene discussed is ERBB2; the disease is hematologic disorder.